NCT04597437View on ClinicalTrials.gov

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Dengue Fever
Interventions
DRUG

Zanamivir

Intravenous zanamivir

OTHER

Placebo

In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Trial Locations (2)

080020

ACTIVE_NOT_RECRUITING

Cien Salud IPS SAS, Barranquilla

RECRUITING

Clinica de la Costa SAS, Barranquilla

Sponsors
All Listed Sponsors
collaborator

Naval Medical Research Center

FED

collaborator

Clinica de la Costa

UNKNOWN

collaborator

Global Disease Research

UNKNOWN

collaborator

Universidad Libre de Barranquilla

UNKNOWN

lead

George Washington University

OTHER

NCT04597437 - Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) | Biotech Hunter | Biotech Hunter